Rein Therapeutics Reports LTI-03 Reduces Lung Scarring in IPF Study
Reuters
Nov 06, 2025
<a href="https://laohu8.com/S/RNTX">Rein Therapeutics</a> Reports LTI-03 Reduces Lung Scarring in IPF Study
Rein Therapeutics Inc. has announced new scientific findings regarding its lead drug candidate, LTI-03, for idiopathic pulmonary fibrosis (IPF). A recently posted preprint on medRxiv describes results from a randomized, dose-escalation clinical study evaluating inhaled LTI-03 in IPF patients. The study assessed safety, pharmacokinetics, and biological activity. According to the report, LTI-03 was generally well tolerated and was associated with reductions in multiple fibrosis-associated biomarkers, as well as preservation of alveolar epithelial type II progenitor cells, which are important for lung repair. These findings build on previous results and provide support for the ongoing global Phase 2 RENEW trial of LTI-03. The results have already been made available in the preprint publication.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rein Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570056-en) on November 06, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.